Value-based care initiatives and ideas have really been growing over the past few years, with outcome-based arrangements being one of the newest ideas. Could this be the year it all takes off? Find out more here. (Source: Matthew Fisher, HiMSS, Linkedin) […]
Trump Told to Hold Pharma’s Feet to the Fire
Senators Tammy Baldwin (D-Wis.) and John McCain (R-Ariz.) are calling on President Trump to make good on his promise to go after pharmaceutical pricing. The Senators are asking Trump to back the Fair Accountability and Innovative Research Drug Pricing Act, introduced last May. Find out more here. […]
FirstWord: The Importance of RWE in Orphan Drugs
FirstWord's The Importance of Real World Evidence in Orphan Drugs explores the three-dimensional value story - clinical, patient and economic - and sheds light on how the core challenges facing orphan drug manufacturers can be overcome. Purchase your copy here. (Source: FirstWord, November 2017) […]
Understanding the Psychology of Pricing
How do customers answer the question, "Is this really worth that?" Deciding how to price your products and/or services is tricky, but knowing how to answer this question is an important first step. Learn more here. (Source: Timothy Murphy, Richard Hayes, Deloitte, 7/25/16) […]
How Much Could Risk-Sharing Contracts Decrease Drug Prices?
The University of Florida (UF) College of Pharmacy, looked at risk-sharing contracts between pharmaceutical manufacturers and health insurance providers as an answer to reducing rising drug prices. Learn more here. (Source: Kaitlynn Ely, AJMC, 2/5/18) […]
Express Scripts Says Per-Person Spending is Decreasing
Express Scripts Holding Co. Inc. recently released their 2017 Drug Trend Report. The report showed a decrease in the increase of per-person prescription drug spending; per-person prescription drug spending rose by only 1.5%, compared to 3.8% in 2016. Find out more here. (Source: Erin Mccallister, […]
Possible Default Drug Formulary Shakes the Pharmaceutical Industry
The Centers for Medicare and Medicaid Services (CMS) recently proposed regulatory initiatives for the 2019 federal health insurance exchanges which could really shake things up in the pharmaceutical industry by promising to consider a federal default prescription drug benefit. How would this affect […]
Pricing & Reimbursement in Neurology: Payer Views
FirstWord looks at the latest views and thinking from payers, at the forefront of the pricing debate, in its Pricing and Reimbursement in Neurology: Payer views, report. Find out more and purchase here. (Source: FirstWord, January 2018) […]
NPC Launches Initiative to Explore Health Care Spending
The National Pharmaceutical Council recently launched a new research-first initiative, Going Below the Surface. The initiative intends to seek constructive answers on how we can spend our health dollars more effectively. Will they be able to move past all the finger pointing? Find out more here. […]
2025 – The End of Hep C in England?
The National Health Service (NHS) in England recently announced an ambitious plan to completely eliminate hepatitis C by 2025, 5 years ahead of the World Health Organization's global target. Find out more here. (Source: Richard Staines, pharmaphorum, 2/1/18) […]
